Kinetic Approach to Pathway Attenuation Using XOMA 052, a Regulatory Therapeutic Antibody That Modulates Interleukin-1β Activity
Marina K. Roell(XOMA (United States)), Mark White(Beatson West of Scotland Cancer Centre)
Cited by 42
Related Papers
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
|The Journal of Infectious Diseases|1999|611